Biogen reports positive spinal muscular atrophy for Spinraza

Biogen has announced new clinical trial data that demonstrates the benefits its drug Spinraza can offer to spinal muscular atrophy patients.

Data presented at the recent Cure SMA 2017 conference in Orlando has underlined the clinically meaningful effectiveness of Spinraza in individuals with spinal muscular atrophy (SMA), regardless of their level of disease severity.

An analysis of the phase III ENDEAR study showed that a greater proportion of infants with SMA on permanent ventilation treated with Spinraza achieved clinical benefits compared to untreated infants, while findings from this study and another phase III trial, CHERISH, indicated that earlier Spinraza treatment may lead to improved outcomes.

Additionally, results from an interim analysis of the phase II NURTURE study showed that Biogen's drug had an impact on event-free survival, measures of motor function and achievement of motor milestones in infants prior to symptom onset.

Dr Wildon Farwell, senior medical director for clinical development at Biogen, said: "We are encouraged to see unprecedented motor function gains in infants on permanent ventilation and a continued favourable benefit-risk profile across a broad population."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.